{"id":192139,"date":"2026-08-10T10:42:11","date_gmt":"2026-08-10T05:12:11","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=192139"},"modified":"2026-08-10T10:42:13","modified_gmt":"2026-08-10T05:12:13","slug":"biocon-vs-gland-pharma-comparison","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/biocon-vs-gland-pharma-comparison\/","title":{"rendered":"Biocon vs Gland Pharma: Which Stock Should You Track"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Biocon MCap Rs 69,262 Cr, PE 188.05x, ROE 1.14%, D\/E 0.45. Gland Pharma MCap Rs 41,996 Cr, PE 40.88x, ROE 9.92%, D\/E 0.03.<\/em><\/p>\n<p>Biocon vs Gland Pharma is a comparison biopharma and specialty pharma investors look up when evaluating two Indian companies with differentiated exposure to biologics and injectables. Biocon is one of India&#8217;s largest biopharma companies, known for insulin, biosimilars of major biologics and its joint venture Biocon Biologics, while Gland Pharma is India&#8217;s largest injectables manufacturer for export, majority-owned by Chinese pharma giant Fosun Pharma, with a B2B model selling to major global generic companies.<\/p>\n<p>This Biocon vs Gland Pharma article covers reach and market position, key products, latest declared results and stock valuation. The Biocon vs Gland Pharma data below is sourced from Groww and public company filings and reflects the most recently available information at the time of writing.<\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/biocon-vs-gland-pharma-comparison\/#Biocon_vs_Gland_Pharma_Reach_and_Market_Position\" title=\"Biocon vs Gland Pharma: Reach and Market Position\">Biocon vs Gland Pharma: Reach and Market Position<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/biocon-vs-gland-pharma-comparison\/#Biocon_vs_Gland_Pharma_Key_Products_and_Business_Mix\" title=\"Biocon vs Gland Pharma: Key Products and Business Mix\">Biocon vs Gland Pharma: Key Products and Business Mix<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/biocon-vs-gland-pharma-comparison\/#Biocon_vs_Gland_Pharma_Latest_Results\" title=\"Biocon vs Gland Pharma: Latest Results\">Biocon vs Gland Pharma: Latest Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/biocon-vs-gland-pharma-comparison\/#Biocon_vs_Gland_Pharma_Stock_and_Valuation\" title=\"Biocon vs Gland Pharma: Stock and Valuation\">Biocon vs Gland Pharma: Stock and Valuation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/biocon-vs-gland-pharma-comparison\/#Biocon_vs_Gland_Pharma_Quick_Comparison_Table\" title=\"Biocon vs Gland Pharma: Quick Comparison Table\">Biocon vs Gland Pharma: Quick Comparison Table<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/biocon-vs-gland-pharma-comparison\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/biocon-vs-gland-pharma-comparison\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/biocon-vs-gland-pharma-comparison\/#What_is_a_biosimilar\" title=\"What is a biosimilar?\">What is a biosimilar?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/biocon-vs-gland-pharma-comparison\/#What_does_Gland_Pharma_make\" title=\"What does Gland Pharma make?\">What does Gland Pharma make?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/biocon-vs-gland-pharma-comparison\/#Who_owns_Gland_Pharma\" title=\"Who owns Gland Pharma?\">Who owns Gland Pharma?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/biocon-vs-gland-pharma-comparison\/#What_is_Biocon_Biologics\" title=\"What is Biocon Biologics?\">What is Biocon Biologics?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/biocon-vs-gland-pharma-comparison\/#Why_is_Biocons_ROE_so_low\" title=\"Why is Biocon&#8217;s ROE so low?\">Why is Biocon&#8217;s ROE so low?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/biocon-vs-gland-pharma-comparison\/#Does_Gland_Pharma_pay_dividends\" title=\"Does Gland Pharma pay dividends?\">Does Gland Pharma pay dividends?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/biocon-vs-gland-pharma-comparison\/#Are_Biocon_and_Gland_in_Nifty_50\" title=\"Are Biocon and Gland in Nifty 50?\">Are Biocon and Gland in Nifty 50?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Biocon_vs_Gland_Pharma_Reach_and_Market_Position\"><\/span><strong>Biocon vs Gland Pharma: Reach and Market Position<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>On the Biocon side of the Biocon vs Gland Pharma comparison, Biocon operates biosimilar and small molecule manufacturing in Bangalore and has Biocon Biologics as a key subsidiary focused on global biosimilar launches across markets including the US, Europe and Emerging Markets. Market capitalisation is Rs 69,262 Cr.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=biocon-vs-glandpharma\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<p>On the Gland Pharma side of the Biocon vs Gland Pharma comparison, Gland Pharma manufactures injectables \u2014 vials, ampoules, prefilled syringes and bags \u2014 for B2B export customers including major US and European generic companies. Market capitalisation is Rs 41,996 Cr.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Biocon_vs_Gland_Pharma_Key_Products_and_Business_Mix\"><\/span><strong>Biocon vs Gland Pharma: Key Products and Business Mix<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>In the Biocon vs Gland Pharma product comparison, Biocon offers: Biocon earns from insulin APIs and formulations, biosimilars of adalimumab, trastuzumab and bevacizumab, and small molecule APIs. EPS is Rs 2.26. P\/E is 188.05x, ROE 1.14 percent, D\/E 0.45. Very thin earnings due to biosimilar investment phase.<\/p>\n<p>For Gland Pharma in this Biocon vs Gland Pharma breakdown: Gland Pharma earns from injectable formulations in vials, ampoules, prefilled syringes and bags. EPS is Rs 62.27. P\/E is 40.88x, ROE 9.92 percent, D\/E 0.03.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Biocon_vs_Gland_Pharma_Latest_Results\"><\/span><strong>Biocon vs Gland Pharma: Latest Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Biocon vs Gland Pharma results for Biocon: Biocon has a market cap of Rs 69,262 Cr and P\/E of 188.05x. ROE is 1.14 percent \u2014 extremely low due to the thin earnings during the biosimilar commercialisation investment phase. The high P\/E is a long-duration bet on biosimilar adoption in the US and Europe.<\/p>\n<p>The Biocon vs Gland Pharma results for Gland Pharma: Gland Pharma has a market cap of Rs 41,996 Cr and P\/E of 40.88x. ROE is 9.92 percent with near-zero debt. Gland&#8217;s B2B injectable model generates stable revenues but growth depends on partner demand and new product approvals.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Compare Biocon and Gland Pharma Fundamentals on the Univest Screener<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Biocon_vs_Gland_Pharma_Stock_and_Valuation\"><\/span><strong>Biocon vs Gland Pharma: Stock and Valuation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Biocon vs Gland Pharma stock comparison uses the latest available market data from Groww. Investors tracking Biocon vs Gland Pharma should verify current prices on NSE or BSE before trading.<\/p>\n<p>Biocon vs Gland Pharma at current valuations: Biocon trades at Rs 69,262 Cr market cap, P\/E 188.05x, ROE 1.14 percent. Gland Pharma trades at Rs 41,996 Cr market cap, P\/E 40.88x, ROE 9.92 percent. Biocon is 1.6 times larger by market cap but has much lower current ROE and far higher P\/E due to biosimilar optionality pricing.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Biocon_vs_Gland_Pharma_Quick_Comparison_Table\"><\/span><strong>Biocon vs Gland Pharma: Quick Comparison Table<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Biocon vs Gland Pharma comparison table below summarises the key metrics covered in this article side by side.<\/p>\n<table style=\"border-collapse: collapse; width: 100%;\">\n<tbody>\n<tr>\n<th style=\"border: 1px solid #ccc; padding: 8px;\">Parameter<\/th>\n<th style=\"border: 1px solid #ccc; padding: 8px;\"><a href=\"https:\/\/univest.in\/stocks\/biocon\/biocon-ltd-share-price-today\">Biocon<\/a><\/th>\n<th style=\"border: 1px solid #ccc; padding: 8px;\"><a href=\"https:\/\/univest.in\/stocks\/gland\/gland-pharma-ltd-share-price-today\">Gland Pharma<\/a><\/th>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Sector<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Biopharma: biosimilars + insulin<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Injectables CDMO\/B2B (US + global export)<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Market Cap<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Rs 69,262 Cr<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Rs 41,996 Cr<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">P\/E Ratio<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">188.05x (optionality priced)<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">40.88x<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">ROE<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">1.14% (investment phase)<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">9.92%<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Debt to Equity<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">0.45<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">0.03<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Business Model<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">B2C biosimilar + API sales<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">B2B injectable manufacturer<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Promoter<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Kiran Mazumdar-Shaw (founder)<\/td>\n<td style=\"border: 1px solid #ccc; padding: 8px;\">Fosun Pharma (China), 57% stake<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Biocon vs Gland Pharma comparison above covers the key data points on reach, products, results and valuation. Biocon vs Gland Pharma is a comparison between a biosimilar optionality play and a steady B2B injectable manufacturer. Biocon is a high-risk, high-potential bet on global biosimilar adoption. Gland Pharma is a cash-generative injectable specialist with a B2B model and near-zero debt. Both face different risk profiles. Investors should review Biocon&#8217;s biosimilar sales traction in the US and Europe, and Gland&#8217;s partner concentration, injectable approval pipeline and Fosun-related risks before taking a view. Consult a SEBI-registered advisor for personalised guidance.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest\/id1543832872\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.android\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Biocon and Gland Pharma live price and get daily stock recommendations.<\/em><\/p>\n<p>SEBI Research Analyst Registration No. INH000013776<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_a_biosimilar\"><\/span><strong>What is a biosimilar?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> A biosimilar is a biological medicine that is highly similar to an approved innovator biological drug and has no clinically meaningful differences. Biosimilars of molecules like adalimumab (Humira), trastuzumab (Herceptin) and bevacizumab (Avastin) can be sold at lower prices after the innovator&#8217;s patent expires.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_does_Gland_Pharma_make\"><\/span><strong>What does Gland Pharma make?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Gland Pharma manufactures injectable pharmaceutical products including vials, ampoules, pre-filled syringes and infusion bags. It primarily supplies to third-party generic companies in the US and Europe under a B2B model.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Who_owns_Gland_Pharma\"><\/span><strong>Who owns Gland Pharma?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Gland Pharma is majority-owned by Fosun Pharma (China), which acquired a controlling stake in 2019. Gland Pharma is listed on Indian exchanges.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Biocon_Biologics\"><\/span><strong>What is Biocon Biologics?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Biocon Biologics is a subsidiary of Biocon focused on developing and commercialising biosimilars globally, including adalimumab (Hadlima), trastuzumab (Ogivri) and others.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_is_Biocons_ROE_so_low\"><\/span><strong>Why is Biocon&#8217;s ROE so low?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Biocon&#8217;s ROE of 1.14 percent reflects thin current earnings as the company is in a heavy investment phase for biosimilar global launches, regulatory filings and capacity building. Investors evaluate Biocon on long-term biosimilar revenue potential.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Does_Gland_Pharma_pay_dividends\"><\/span><strong>Does Gland Pharma pay dividends?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Yes. Gland Pharma pays a dividend yield of approximately 0.78 percent.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Are_Biocon_and_Gland_in_Nifty_50\"><\/span><strong>Are Biocon and Gland in Nifty 50?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Neither Biocon nor Gland Pharma is in Nifty 50. Biocon is in the Nifty Pharma index.<\/p>\n<div class=\"faq-schema\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Biocon vs Gland Pharma compared on biosimilar and injectable portfolios, ROE and valuation. Full data-backed breakdown for Indian biopharma investors.<\/p>\n","protected":false},"author":36,"featured_media":192138,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-192139","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["192138"],"_edit_lock":["1786338735:36"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["81"],"rank_math_title":["Biocon vs Gland Pharma: Which Biopharma Stock Should You Track"],"rank_math_description":["Biocon vs Gland Pharma compared on biosimilar and injectable portfolios, ROE and valuation. Full data-backed breakdown for Indian biopharma investors."],"rank_math_focus_keyword":["Biocon vs Gland Pharma"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_edit_last":["36"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["35206"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/biocon-vs-gland-pharma-comparison.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/192139","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/36"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=192139"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/192139\/revisions"}],"predecessor-version":[{"id":192390,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/192139\/revisions\/192390"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/192138"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=192139"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=192139"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=192139"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}